 |
|
|
|
| |
 |
|
|
| |
Working with Pharmarama to manage the demand for your unlicensed medicines allows you to retain control of supply channels and derive an early flow of information and revenue. This is implemented under the 'Named Patient Program' which is more commonly known as 'Compassionate Use'.
The Named Patient Program allows for the supply and use of unlicensed medicines under strictly limited conditions:
an unlicensed product can be supplied to meet the special needs of individual patients
where a licensed equivalent does not exist. These medicines include drugs which are not yet licensed in the identified territory, as well as investigational drugs awaiting regulatory approval. Named Patient Program may be indicated for orphan drugs, oncology, infectious disease, critical care or metabolic disease therapies. Our team at Pharmarama create these access programs to provide patients and healthcare professionals with unique solutions to drug supply issues. We know that significant early benefits (revenue and data to support submissions) can accrue from entering, in a controlled and responsive way, markets where your products offer clinical benefits, but are currently unlicensed. A Named Patient Program for your product is a proven way of generating additional return from your investment as well as considerably accelerating demand at the time of market authorization. Pharmarama Named Patient Program enables you to:Ethically respond to global patient demand, even in locations where a medicine is awaiting regulatory approval Gather valuable real-life data, such as demographics and patient safety data that can support licensing and post-launch programs Build early product awareness and develop relationships with opinion leaders and disease advocates Develop experience and gain support from regulatory agencies, patients and physicians Implement commercial pricing and distribution control Legally and ethically achieve pre-launch revenue streams
|
|
|
